The trial included expansion groups for microsatellite stable-colorectal cancer, or MSS CRC, recurrent platinum refractory/resistant ovarian, sarcoma, and PD-(L)1 relapsed/refractory non-small cell lung cancer, or NSCLC, the company said.
Data show that overall response rates ranged from 22% in MSS-CRC to 60% in PD-(L)1 refractory NSCLC and that botensilimab was well tolerated during the study, the company said.
Agenus also said that it has started phase 2 trials of botensilimab in advanced MSS-CRC and advanced melanoma.
The company's shares rose nearly 18% in recent trading activity.
Price: 2.96, Change: +0.44, Percent Change: +17.73
|NV5 Global Buys Bromley Cook Engineering|
|Upstart to Cut 20% of Workforce; Shares Fall|
|HomeTrust Bancshares Obtains Regulatory Approvals fo...|
|Dallas Fed Services Index Improves in January, Secto...|
|Tech, Telecoms Stocks Weigh Down Asian Equities in T...|